A phase I study of hepatic arterial infusion using difluoromethylornithine. 1989

A Lipton, and H A Harvey, and J Glenn, and W A Weidner, and M Strauss, and S E Miller, and J B Taylor, and D White-Hershey, and J L Barlow
Division of Oncology, Milton S. Hershey Medical Center, Pennsylvania State University, Hershey 17033.

Ten patients with metastatic disease to the liver were treated with difluoromethylornithine (DFMO) administered by continuous hepatic arterial infusion. Two of nine evaluable patients had an objective partial response. Stable disease was recorded in three patients. Ototoxicity was encountered in all patients who received a daily dose of DFMO equal to or greater than 1.0 g/m2.

UI MeSH Term Description Entries
D007261 Infusions, Intra-Arterial Regional infusion of drugs via an arterial catheter. Often a pump is used to impel the drug through the catheter. Used in therapy of cancer, upper gastrointestinal hemorrhage, infection, and peripheral vascular disease. Infusions, Regional Arterial,Infusions, Intra Arterial,Infusions, Intraarterial,Arterial Infusion, Intra,Arterial Infusion, Regional,Arterial Infusions, Intra,Arterial Infusions, Regional,Infusion, Intra Arterial,Infusion, Intra-Arterial,Infusion, Intraarterial,Infusion, Regional Arterial,Intra Arterial Infusion,Intra Arterial Infusions,Intra-Arterial Infusion,Intra-Arterial Infusions,Intraarterial Infusion,Intraarterial Infusions,Regional Arterial Infusion,Regional Arterial Infusions
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D006312 Hearing Loss, Bilateral Partial hearing loss in both ears. Deafness Bilateral,Bilateral Deafness,Bilateral Hearing Loss,Bilateral Hearing Losses,Bilateral, Deafness,Bilaterals, Deafness,Deafness Bilaterals,Deafness, Bilateral,Loss, Bilateral Hearing
D006499 Hepatic Artery A branch of the celiac artery that distributes to the stomach, pancreas, duodenum, liver, gallbladder, and greater omentum. Arteries, Hepatic,Artery, Hepatic,Hepatic Arteries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000518 Eflornithine An inhibitor of ORNITHINE DECARBOXYLASE, the rate limiting enzyme of the polyamine biosynthetic pathway. Difluoromethylornithine,alpha-Difluoromethylornithine,DL-alpha-Difluoromethylornithine,Eflornithine Hydrochloride,Eflornithine Monohydrochloride, Monohydrate,MDL-71,782 A,Ornidyl,RMI 71782,Vaniqa,alpha-Difluoromethyl Ornithine,DL alpha Difluoromethylornithine,MDL 71,782 A,MDL71,782 A,Ornithine, alpha-Difluoromethyl,alpha Difluoromethyl Ornithine,alpha Difluoromethylornithine

Related Publications

A Lipton, and H A Harvey, and J Glenn, and W A Weidner, and M Strauss, and S E Miller, and J B Taylor, and D White-Hershey, and J L Barlow
February 2002, Clinical cancer research : an official journal of the American Association for Cancer Research,
A Lipton, and H A Harvey, and J Glenn, and W A Weidner, and M Strauss, and S E Miller, and J B Taylor, and D White-Hershey, and J L Barlow
September 2009, European journal of cancer (Oxford, England : 1990),
A Lipton, and H A Harvey, and J Glenn, and W A Weidner, and M Strauss, and S E Miller, and J B Taylor, and D White-Hershey, and J L Barlow
January 2004, Anticancer research,
A Lipton, and H A Harvey, and J Glenn, and W A Weidner, and M Strauss, and S E Miller, and J B Taylor, and D White-Hershey, and J L Barlow
May 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
A Lipton, and H A Harvey, and J Glenn, and W A Weidner, and M Strauss, and S E Miller, and J B Taylor, and D White-Hershey, and J L Barlow
January 2001, Tumori,
A Lipton, and H A Harvey, and J Glenn, and W A Weidner, and M Strauss, and S E Miller, and J B Taylor, and D White-Hershey, and J L Barlow
November 2003, Japanese journal of clinical oncology,
A Lipton, and H A Harvey, and J Glenn, and W A Weidner, and M Strauss, and S E Miller, and J B Taylor, and D White-Hershey, and J L Barlow
August 1991, Gan to kagaku ryoho. Cancer & chemotherapy,
A Lipton, and H A Harvey, and J Glenn, and W A Weidner, and M Strauss, and S E Miller, and J B Taylor, and D White-Hershey, and J L Barlow
February 2010, American journal of clinical oncology,
A Lipton, and H A Harvey, and J Glenn, and W A Weidner, and M Strauss, and S E Miller, and J B Taylor, and D White-Hershey, and J L Barlow
December 2015, Liver cancer,
A Lipton, and H A Harvey, and J Glenn, and W A Weidner, and M Strauss, and S E Miller, and J B Taylor, and D White-Hershey, and J L Barlow
December 2011, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver,
Copied contents to your clipboard!